- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lisata Therapeutics Inc (LSTA)
Lisata Therapeutics Inc stock price live, this page displays NASDAQ LSTA stock exchange data. View the LSTA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lisata Therapeutics Inc real time stock price chart below.
What Is the Lisata Therapeutics Inc Stock Price Today?
The Lisata Therapeutics Inc stock price today is 4.0100.
What Is the Stock Symbol for Lisata Therapeutics Inc?
The stock ticker symbol for Lisata Therapeutics Inc is LSTA.
Is LSTA the Same as $LSTA?
$LSTA is a common way to refer to the Lisata Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Lisata Therapeutics Inc Trade On?
Lisata Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Lisata Therapeutics Inc a Good Stock to Buy?
Determining whether Lisata Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Lisata Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LSTA quote. (ISIN: US1280583022)
What Is the Lisata Therapeutics Inc Stock Price Today?
The Lisata Therapeutics Inc stock price today is 4.0100.
What Is the Stock Symbol for Lisata Therapeutics Inc?
The stock ticker symbol for Lisata Therapeutics Inc is LSTA.
Is LSTA the Same as $LSTA?
$LSTA is a common way to refer to the Lisata Therapeutics Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Lisata Therapeutics Inc Trade On?
Lisata Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Lisata Therapeutics Inc a Good Stock to Buy?
Determining whether Lisata Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Lisata Therapeutics Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LSTA quote. (ISIN: US1280583022)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.6750
4.6500
52 wk Range
1.8100
5.0700
LSTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.67504.6500
52 wk Range
1.81005.0700
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LSTA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
9.5000
Upside
+136.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics Inc Earnings Call Summary for Q3/2025
- Lisata Therapeutics reported Q3 2025 EPS of -$0.49, beating analyst expectations of -$0.59, but stock fell 7.26% in aftermarket trading to $2.17.
- Operating expenses decreased 17.3% year-over-year to $4.4 million, with R&D expenses down 22.9% and net losses reduced to $4.2 million from $4.9 million.
- Despite positive earnings surprise of 16.95%, investor concerns persist about ongoing net losses and the company's ability to secure funding for future trials.
- Management anticipates upcoming phase 3 trials for sirtepotide and is focused on securing pharmaceutical partnerships to fund clinical programs.
- CEO Dr. David Mazzo highlighted positive results across various studies, while CMO Dr. Kristen Buck emphasized sirtepotide's ability to modify tumor microenvironments.
Last Updated: 11/06/2025, 05:49 PM
Read Full TranscriptCompare LSTA to Peers and Sector
Metrics to compare | LSTA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLSTAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −2.6x | −0.5x | |
PEG Ratio | −0.12 | −0.11 | 0.00 | |
Price / Book | 2.8x | 2.2x | 2.6x | |
Price / LTM Sales | 240.7x | 10.3x | 3.2x | |
Upside (Analyst Target) | 136.9% | 69.2% | 47.6% | |
Fair Value Upside | Unlock | 5.2% | 6.1% | Unlock |
Analyst Ratings
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 9.5000
(+136.91% Upside)
Earnings
Latest Release
Mar 31, 2026
EPS / Forecast
-0.34 / -0.63
Revenue / Forecast
100K / --
People Also Watch
FAQ
What Is the Lisata Therapeutics (LSTA) Stock Price Today?
The Lisata Therapeutics stock price today is 4.0100 USD.
What Stock Exchange Does Lisata Therapeutics Trade On?
Lisata Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Lisata Therapeutics?
The stock symbol for Lisata Therapeutics is "LSTA."
What Is the Lisata Therapeutics Market Cap?
As of today, Lisata Therapeutics market cap is 35.4100M USD.
What Is Lisata Therapeutics's Earnings Per Share (TTM)?
The Lisata Therapeutics EPS (TTM) is -1.9093.
When Is the Next Lisata Therapeutics Earnings Date?
Lisata Therapeutics will release its next earnings report on May 07, 2026.
From a Technical Analysis Perspective, Is LSTA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Lisata Therapeutics Stock Split?
Lisata Therapeutics has split 6 times.
How Many Employees Does Lisata Therapeutics Have?
Lisata Therapeutics has 21 employees.
What is the current trading status of Lisata Therapeutics (LSTA)?
As of Apr 15, 2026, Lisata Therapeutics (LSTA) is trading at a price of 4.0100 USD, with a previous close of 4.5300 USD. The stock has fluctuated within a day range of 3.6750 USD to 4.6500 USD, while its 52-week range spans from 1.8100 USD to 5.0700 USD.
What Is Lisata Therapeutics (LSTA) Price Target According to Analysts?
The average 12-month price target for Lisata Therapeutics is 9.5000 USD, with a high estimate of 15 USD and a low estimate of 4 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +136.91% Upside potential.
What Is the LSTA After Hours Price?
LSTA's last after hours stock price is 3.8654 USD, the stock has decreased by -0.1446, or -3.6100%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.